News

Top-line results are expected next month from a Phase 2b clinical trial testing whether the investigational oral therapy mesdopetam can ease levodopa-induced dyskinesia, or involuntary movements, in people with Parkinson’s disease. IRLAB Therapeutics, the therapy’s original developer and sponsor of the trial, announced that the final participant…

Among people diagnosed with melanoma, a type of skin cancer, the tumor is twice as likely to be found along the head or neck if they also have Parkinson’s disease, a study found. These findings support the importance of screening these regions for more accurate melanoma surveillance in Parkinson’s…

Nitrase Therapeutics has partnered with HitGen in the search for novel therapies that suppress nitrases, a class of enzymes discovered by Nitrase. Nitrases are responsible for nitration, a type of biochemical modification of proteins that is linked to cellular stress and can change that protein’s structure, function, and…

Both type 2 diabetes and prediabetes — a condition in which blood sugar levels are abnormally high, but not high enough to constitute diabetes — are significantly associated with poorer cognition in people with Parkinson’s disease, according to a small study from South Korea. These findings add to previous…

Using amantadine — a parkinsonian medication that has also antiviral activity — does not reduce the occurrence of COVID-19 or its severity among people with Parkinson’s disease, a Polish study found. Rather, the researchers observed that COVID-19 was less common among people over age 50 age, and those with…

Deferiprone, an iron chelator (binder) therapy, does not slow the progression of Parkinson’s disease in newly diagnosed patients who have never received treatment, according to data from a Phase 2 clinical trial. Instead, after about nine months of treatment in these patients, deferiprone was associated with a worsening of…

Levels of alpha-synuclein, beta-amyloid, and neurofilament light chain (NfL) in the cerebrospinal fluid (CSF) that surrounds the brain and the spinal cord can help identify Parkinson’s disease and distinguish it from atypical parkinsonism, according to a review study. The study, “A meta-analysis of the diagnostic…

The U.S. Food and Drug Administration (FDA) has put a hold on clinical trials of IkT-148009, an experimental oral therapy that Inhibikase Therapeutics is developing for Parkinson’s disease and other related and non-related conditions. The hold comes just a few months after Inhibikase started dosing Parkinson’s patients…

Vibra Healthcare is partnering with the neurotechnology company MindMaze to provide digital neurotherapeutic tools for people with neurological disorders both in the clinic and at home. The initiative will start with patients at select Vibra hospitals in Kentucky and California. MindMaze’s digital health solutions aim to help people with…

NeuroOne Medical Technologies announced it has successfully completed a feasibility study of its OneRF ablation system, which uses implanted electrodes to destroy targeted regions of the brain — and may help to control tremor in people with Parkinson’s disease — in animal models. The company is planning…